|
Reteplase
Product Approval Information - Licensing Action
Proper name: Reteplase
Tradename: Retavase
Manufacturer: Boehringer Mannheim GmbH, Werk Penzberg, Federal Republic of Germany, License #1211
Indication for Use: In the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with AMI
Approval Date: 10/30/96
Type of submission: Biologics license application
Approval Letter (PDF),
(Text)
Reviews
Clinical Review
(PDF)
Pharmacokinetics Review
(PDF)
Pharmacologist's Review
(PDF)
Product Review (PDF)
Last Updated: 3/6/2001
 Back
to Top 
Back to Index
Updated: September 25, 2003 |
